Treatment of Non-criteria Manifestations in Antiphospholipid Syndrome

Ugolini-Lopes, Michelle Remião; Criado, Paulo Ricardo; Parsi, Kurosh; Küçükkaya, Reyhan Diz; Amigo, Mary‐Carmen; Tektonidou, Maria G; Andrade, Danieli

doi:10.1007/978-3-319-55442-6_13

Cited by 4 publications

(2 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with adrenal hemorrhage/infarct, anticoagulation should be started (or not stopped) unless life‐threatening bleeding occurs. In livedoid vasculopathy, antiplatelet agents (low‐dose aspirin, dipyridamole, pentoxifylline, clopidogrel, or ticlopidine) can be considered as add‐on therapy based on case reports (60). 2 A decision regarding anticoagulation with or without low‐dose aspirin should be made based on the assessment of bleeding risk.…”

Section: Clinical Challengementioning

confidence: 99%

Expert Perspective: Management of Microvascular and Catastrophic Antiphospholipid Syndrome

Erkan

2021

Arthritis & Rheumatology

View full text Add to dashboard Cite

Clinical challengeA 50-year-old man with antiphospholipid syndrome (APS) presents to your office for the first time with a 3-month history of worsening dyspnea, dry cough, and early morning blood-tinged sputum. His APS diagnosis was based on an unprovoked left leg deep vein thrombosis, 4 years prior to the presentation, with persistent (multiple occasions) triple-antiphospholipid antibody (aPL) positivity, defined as lupus anticoagulant (LAC) positivity while not receiving anticoagulation therapy, high-titer (≥80 units) IgG anticardiolipin antibodies (aCL), and high-titer IgG anti-β 2 -glycoprotein I (anti-β 2 GPI). He has no other past medical history, and he is receiving warfarin with a target international normalized ratio (INR) of 2.5-3. Physical examination is normal except for livedo racemosa around his knees. His platelet count is 99 × 10 3 /ml (chronic; fluctuating 80-120 × 10 3 /ml since the APS diagnosis), INR is 3, hemoglobin, creatinine, and complement levels are normal, and spot urine protein:creatinine ratio is 0.3. His primary care physician ordered a chest radiograph, which shows extensive patchy bilateral airspace opacities, and a chest computed tomography (CT) scan, which shows diffuse bilateral ground-glass opacities.

show abstract

Section: Clinical Challengementioning

confidence: 99%

Expert Perspective: Management of Microvascular and Catastrophic Antiphospholipid Syndrome

Erkan

2021

Arthritis & Rheumatology

View full text Add to dashboard Cite

show abstract

“…APS patients are characterized by a wide spectrum of clinical manifestations such as livedo reticularis, migraine, epilepsy, thrombocytopenia, valvular heart disease, hemolytic anemia, and nephropathy. These clinical presentations, although frequent, are not included in classification criteria [73][74][75].…”

Section: Antiphospholipid Syndromementioning

confidence: 99%

MicroRNA (miRNA): A New Dimension in the Pathogenesis of Antiphospholipid Syndrome (APS)

Kotyla

Islam

2020

IJMS

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are single-stranded, endogenous RNA molecules that play a significant role in the regulation of gene expression as well as cell development, differentiation, and function. Recent data suggest that these small molecules are responsible for the regulation of immune responses. Therefore, they may act as potent modulators of the immune system and play an important role in the development of several autoimmune diseases. Antiphospholipid syndrome (APS) is an autoimmune systemic disease characterized by venous and/or arterial thromboses and/or recurrent fetal losses in the presence of antiphospholipid antibodies (aPLs). Several lines of evidence suggest that like other autoimmune disorders, miRNAs are deeply involved in the pathogenesis of APS, interacting with the function of innate and adaptive immune responses. In this review, we characterize miRNAs in the light of having a functional role in the immune system and autoimmune responses focusing on APS. In addition, we also discuss miRNAs as potential biomarkers and target molecules in treating APS.

show abstract

Management of Non-criteria Manifestations in Antiphospholipid Syndrome

Xourgia

Tektonidou

2020

Curr Rheumatol Rep

View full text Add to dashboard Cite

Treatment of Non-criteria Manifestations in Antiphospholipid Syndrome

Cited by 4 publications

References 100 publications

Expert Perspective: Management of Microvascular and Catastrophic Antiphospholipid Syndrome

Expert Perspective: Management of Microvascular and Catastrophic Antiphospholipid Syndrome

MicroRNA (miRNA): A New Dimension in the Pathogenesis of Antiphospholipid Syndrome (APS)

Management of Non-criteria Manifestations in Antiphospholipid Syndrome

Contact Info

Product

Resources

About